DELRAY BEACH, Fla., March 12, 2025 /PRNewswire/ -- The global Clinical Trial Services Market, valued at US$60.76 billion in 2024, is forecasted to grow at a robust CAGR of 8.9%, reaching US$66.59 ...

The START Center for Cancer Research ("START"), a global leader in early-phase oncology clinical trials, announces the expansion of its network with the acquisition of Carolina Urologic Research ...

IQVIA (NYSE:IQV), a leading global provider of AI-powered analytics, technology solutions and clinical research services to the healthcare and life sc ...

Investing.com -- Shares of Incyte Corporation (NASDAQ: INCY) fell 14% after the biopharmaceutical company announced topline results from two Phase 3 clinical trials of povorcitinib in patients with ...

YPrime, the leading pioneer in clinical trial technology, today announced it has earned a top-tier EcoVadis rating and medal, ...

Incyte (Nasdaq: INCY) today announced positive topline results from its pivotal Phase 3 STOP-HS clinical trial program evaluating the safety and efficacy of povorcitinib (INCB054707), an oral ...

A new precision oncology paper was published in Oncotarget, Volume 16, on March 12, 2025, titled “Worldwide Innovative ...

CMND-100 is Clearmind's proprietary MEAI-based oral drug candidate, developed as a potential breakthrough treatment for AUD. Unlike traditional treatment methods, CMND-100 is designed to offer a novel ...